Mara Goldstein
Stock Analyst at Mizuho
(2.81)
# 1,659
Out of 4,820 analysts
75
Total ratings
42.86%
Success rate
6.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $7.49 | +6.81% | 7 | Apr 9, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $26 → $32 | $6.43 | +397.67% | 2 | Jan 31, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $8.28 | +407.25% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $10.45 | +378.47% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.32 | +237.84% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $59.17 | +30.13% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.39 | +403.60% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.28 | +525.00% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.40 | +2,923.43% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $3.51 | +754.70% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $0.78 | +674.09% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.63 | -3.58% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.18 | +6,443.08% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $1.44 | +1,288.89% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $82.74 | +57.12% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $0.71 | +180.66% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.32 | +809.09% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.26 | +3,309.09% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $40.43 | -50.53% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $5.02 | +856.18% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.56 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.26 | +166.16% | 1 | Oct 12, 2017 |
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $7.49
Upside: +6.81%
Kura Oncology
Jan 31, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $6.43
Upside: +397.67%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $8.28
Upside: +407.25%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $10.45
Upside: +378.47%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.32
Upside: +237.84%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $59.17
Upside: +30.13%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.39
Upside: +403.60%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.28
Upside: +525.00%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.40
Upside: +2,923.43%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $3.51
Upside: +754.70%
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $0.78
Upside: +674.09%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.63
Upside: -3.58%
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.18
Upside: +6,443.08%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.44
Upside: +1,288.89%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $82.74
Upside: +57.12%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $0.71
Upside: +180.66%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.32
Upside: +809.09%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.26
Upside: +3,309.09%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $40.43
Upside: -50.53%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $5.02
Upside: +856.18%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $19.56
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.26
Upside: +166.16%